Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cardiovascular Disease: full-pipeline trial registry
20 of 138 indexed Cardiovascular Disease trials are currently recruiting.
Corpus placement: #83 of 28,707 conditions by registered trial count.
138 US clinical trials · 20 currently recruiting · #83 of 28,707 conditions by registered trial count
Cardiovascular Disease: 138 US clinical trials tracked, 20 recruiting.
Cardiovascular Disease is the subject of 138 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 22 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is VA Office of Research and Development, running 10 of these trials.
Enrollment posture brief
Registry condition cardiovascular-disease
OPEN 20 | RECR 14% | LATE 22 | EARLY 15 | RANK #83 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Acute Coronary Syndrome (15% recruiting · 41 trials)
Cardiovascular Disease lists 20 open slots (14% of 138 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cardiovascular Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cardiovascular Disease is recruiting below its size-band peers.
20 of 138 indexed trials (14.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cardiovascular Disease trials is spread across many organizations.
VA Office of Research and Development accounts for 10 of 138 trials (7.2%). 84 distinct sponsors appear on at least one study for this condition label.
-
Typical Cardiovascular Disease enrolment sits around 120 participants.
Median target enrolment is 120 among the 138 trials that report a genuine target (sentinel values excluded). 59 of those (42.8%) plan for fewer than 100 participants.
-
Cardiovascular Disease splits between interventional and observational designs.
93 interventional and 45 observational studies make up this index (67.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
138 total, page 1 of 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
AstraZeneca
NCT07000357
Cardiology Biobank Registry
Emory University
NCT00378924
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Amgen
NCT07136012
Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)
National Heart, Lung, and Blood Institute (NHLBI)
NCT02543996
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
McMaster University
NCT03127631
Technical Development of Cardiovascular Magnetic Resonance Imaging
National Heart, Lung, and Blood Institute (NHLBI)
NCT04927429
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03374215
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank
National Heart, Lung, and Blood Institute (NHLBI)
NCT02706639
WISE CVD - Continuation (WISE HFpEF)
Cedars-Sinai Medical Center
NCT02582021
Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention
National Heart, Lung, and Blood Institute (NHLBI)
NCT01927783
Randomized Trial of SGLT2i in Heart Transplant Recipients
VA Office of Research and Development
NCT06625073
Natural History Study of CADASIL
National Heart, Lung, and Blood Institute (NHLBI)
NCT05072483
Beta-Blocker Influences on Inflammatory and Neural Responses to Stress
University of North Carolina, Chapel Hill
NCT06263452
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
National Heart, Lung, and Blood Institute (NHLBI)
NCT03372733
Gauging Outcomes of Total Milk Ingestion on Lipid and gControl
University of California, San Francisco
NCT07087184
A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
University of Connecticut
NCT07238556
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
National Heart, Lung, and Blood Institute (NHLBI)
NCT04216342
Single-tracer Multiparametric PET Imaging
University of California, Davis
NCT06014515
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT05440422
Determining the Benefits of Exercise on Cardiovascular Risk in PTSD
Massachusetts General Hospital
NCT07260032
Gulf Long-Term Follow-Up Study
National Institute of Environmental Health Sciences (NIEHS)
NCT01287000
Database Registry of the Intermountain Heart Collaborative Study
Intermountain Health Care
NCT00406185
Vitamin D and Omega-3 Trial (VITAL)
Brigham and Women's Hospital
NCT01169259
VITAL Rhythm Study
Brigham and Women's Hospital
NCT02178410
Hispanic Community Health Study / Study of Latinos
National Heart, Lung, and Blood Institute (NHLBI)
NCT02060344
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Novo Nordisk A/S
NCT05669755
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Amgen
NCT05284747
Technical Development for Pediatric Cardiovascular MRI
Children's National Research Institute
NCT02892136
The Miami Heart Study at Baptist Health South Florida
Baptist Health South Florida
NCT02508454
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
National Institute on Aging (NIA)
NCT01323322
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
AstraZeneca
NCT07000123
Epidemiology of Sleep-Disordered Breathing in Adults
University of Wisconsin, Madison
NCT00005557
Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease
The University of Texas Health Science Center, Houston
NCT00756379
Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)
Marymount University
NCT07180147
Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction
Cedars-Sinai Medical Center
NCT00832702
Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation
VA Office of Research and Development
NCT03625349
Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy
Johns Hopkins University
NCT02694094
Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk
NYU Langone Health
NCT05828849
Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)
Augusta University
NCT02115724
Home-Based Measures of Physical Activity and Body Composition
M.D. Anderson Cancer Center
NCT00542438
Implementation of Practice Standards for ECG Monitoring
Yale University
NCT01269736
PeriOperative ISchemic Evaluation-2 Trial
Hamilton Health Sciences Corporation
NCT01082874
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Eli Lilly and Company
NCT01394952
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)
Sanofi
NCT00249795
Long Term Health Outcomes of Women Veterans' Service During the Vietnam Era
VA Office of Research and Development
NCT00958061
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00064753
Cardiogenomics Registry
Piedmont Healthcare
NCT00861575
World Trade Center (WTC) CHEST
Icahn School of Medicine at Mount Sinai
NCT01466218
Cholesterol and Pharmacogenetic Study
UCSF Benioff Children's Hospital Oakland
NCT00451828
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
AstraZeneca
NCT01408303
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 14 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Cardiovascular Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cardiovascular Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cardiovascular Disease page
138 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 20 Cardiovascular Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- VA Office of Research and Development sponsors the most Cardiovascular Disease trials on record, review their full trial history before evaluating a specific study. See VA Office of Research and Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cardiovascular Disease condition card totals 138 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.